Dual modulating drugs with FXR agonism have avoided this problem and are demonstrating promising actions to combat kidney and cardiovascular diseases (Miyazaki-Anzai et al., 2010; Stavniichuk et al., 2020). The gene discussed is NR1H4; the disease is cardiovascular disorder.